tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2023 Aug;19(2):2256510.
doi: 10.1080/21645515.2023.2256510. Epub 2023 Oct 4. Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
Xia Wei[SUP] 1 [/SUP], Xue Tan[SUP] 1 [/SUP], Qinghu Guan[SUP] 2 [/SUP], Ruizhi Zhang[SUP] 2 [/SUP], Shiguang Lei[SUP] 1 2 [/SUP], Shaofeng Wei[SUP] 1 [/SUP]
Affiliations
Evidence of the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months has been emerging. To evaluate the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months in a systematic review and meta-analysis. This meta-analysis included 12 studies with 6722 participants receiving QIV, 3575 participants receiving TIV, 4249 participants receiving full-dose QIV (F-QIV), and 3722 participants receiving half-dose QIV (H-QIV). Among children aged 6 to 35 months, QIV produces a better Immunogenicity against influenza B vaccine strains not contained in TIV. However, injection site reaction was more common for QIV, F-QIV showed superior efficacy for the B lineage, but fever and injection site pain was more frequently reported for F-QIV than H-QIV. These data support the immunogenicity and safety of quadrivalent inactivated influenza vaccine among children aged 6 to 35 months.
Keywords: Random clinical trials; children aged 6 to 35 months; immunogenicity; influenza vaccine; safety; systematic review.
. 2023 Aug;19(2):2256510.
doi: 10.1080/21645515.2023.2256510. Epub 2023 Oct 4. Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
Xia Wei[SUP] 1 [/SUP], Xue Tan[SUP] 1 [/SUP], Qinghu Guan[SUP] 2 [/SUP], Ruizhi Zhang[SUP] 2 [/SUP], Shiguang Lei[SUP] 1 2 [/SUP], Shaofeng Wei[SUP] 1 [/SUP]
Affiliations
- PMID: 37794647
- DOI: 10.1080/21645515.2023.2256510
Evidence of the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months has been emerging. To evaluate the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months in a systematic review and meta-analysis. This meta-analysis included 12 studies with 6722 participants receiving QIV, 3575 participants receiving TIV, 4249 participants receiving full-dose QIV (F-QIV), and 3722 participants receiving half-dose QIV (H-QIV). Among children aged 6 to 35 months, QIV produces a better Immunogenicity against influenza B vaccine strains not contained in TIV. However, injection site reaction was more common for QIV, F-QIV showed superior efficacy for the B lineage, but fever and injection site pain was more frequently reported for F-QIV than H-QIV. These data support the immunogenicity and safety of quadrivalent inactivated influenza vaccine among children aged 6 to 35 months.
Keywords: Random clinical trials; children aged 6 to 35 months; immunogenicity; influenza vaccine; safety; systematic review.